000			na a22 4500
999			_c529 _d529
003			PC529
005			20210625062754.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_aBautista, José M. _91902 _eInstituto de Investigación i+12
100			_aDíez, Amalia _91901 _eInstituto de Investigación i+12
100			_aLinares Gómez, María _91898 _eInstituto de Investigación i+12
100			_aMarín García, Patricia _92240 _eInstituto de Investigación i+12
100			_aPuyet, Antonio _91900 _eInstituto de Investigación i+12
245	0	0	_aEstandarización de un modelo murino de malaria cerebral en fases clínicas para la evaluación de terapias antimaláricas y de rescate. _h[artículo]
260			_bAnales De La Real Academia Nacional De Farmacia, _c2013
300			_a79(2):274-92.
500			_aFormato Vancouver: Martínez G, Linares M, Marín-García P, Pérez-Benavente S, Puyet A, Bautista JM et al. Estandarización de un modelo murino de malaria cerebral en fases clínicas para la evaluación de terapias antimaláricas y de rescate. An Real Acad Nac Farm. 2013;79(2):274-92.
501			_aNO PMID
504			_aContiene 40 referencias
520			_aCerebral malaria (CM) is included among the more devastating SNC infectious diseases due to its high mortality and severe sequelae in children. Currently, no specific pharmacological treatment for CM or rescue therapy for neurocognitive residual injury are available, and research on this topic has been hampered due to the lack of well-defined experimental models. In the present study we have characterized the CM murine infection phenotypically, evaluating clinical parameters, which allowed establishing a model encompassing four distinct disease stages. This protocol provides the experimental framework to study adjunctive neuroprotective therapies that may prevent and/or eliminate the neurological sequelae in individuals surviving CM.
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/5/pc529.pdf _ySolicitar documento
942			_n0 _2ddc _cART